Menlo Therapeutics is a Menlo Park, Calif.-based clinical-stage pharmaceutical company focused on developing serlopitant, a once-daily oral NK-1 receptor antagonist. Serlopitant is investigational for the treatment of chronic pruritus and refractory chronic cough. The company is advancing the drug for pruritus associated with atopic dermatitis, psoriasis and prurigo nodularis, as well as for refractory chronic cough. Menlo has completed two phase 2 trials: TCP-101 (chronic pruritus from multiple causes) and TCP-102 (pruritus associated with prurigo nodularis). The company raised $50M in a Series C financing to support further development of serlopitant. In conjunction with the financing, venBio’s Aaron Royston, MD will join Menlo’s board of directors, indicating investor involvement in the program.

Total raised

$50M

Funding rounds

1

Latest round

Series C

Latest activity

Jul 2017